Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
GTBP Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 15, 2026
Report Source: 2026 1st Quarter Report
GT Biopharma Inc. Stock Analysis GTBP
United States Health Care Nano Cap Report: GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Read More GT Biopharma Inc (GTBP) Chart
Key Statistics of GT Biopharma Inc (GTBP)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.51Volume
1.09MP/E Ratio (TTM)
-52 Week Range
Market Cap
15.62MAvg. Volume
1.63MDividend Yield
-Financial Metrics & Statements of GT Biopharma Inc (GTBP)
FAQ's for GT Biopharma Inc (GTBP)
- According to Musaffa’s Shariah screening methodology, GT Biopharma Inc (GTBP) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes GT Biopharma Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in GT Biopharma Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of GT Biopharma Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of GT Biopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of GT Biopharma Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.